R&D shakeup: Merck taps former Amgen exec Perlmutter to replace Kim
This article was originally published in Scrip
Executive Summary
There may be an increased level of anxiety among research staff at Merck & Co. over the next few months as former Amgen executive Roger Perlmutter comes on board to replace Peter Kim as head of R&D. Perlmutter will have “broad discretion” to kill or move existing drug programs forward, according to Merck spokesperson Steven Cragle.